Zika virus reference materials
Dependable solutions for critical emerging infectious diseases
ATCC is supporting Zika virus research efforts, such as vaccine efficacy testing and the development of detection assays, with an expanding collection of Zika virus reference materials and solutions, to include:
- In vivo and tissue culture–adapted strains
- Genomic and synthetic nucleic acid preparations
- Host cell lines and reagents
- Custom solutions for expansion, titering, and banking
Download our white paper featuring comparative detection methods for Zika, Chikungunya, and Dengue viruses, and find out how ATCC can help with your next molecular-based assay.
ATCC Zika virus reference materials
||Zika virus strain MR 766
||Zika virus strain MR 766 (Tissue culture-adapted from ATCC® VR-84™)
||Zika virus strain IBH 30656
||Zika virus strain PRVABC59
||Heat inactivated Zika virus strain PRVABC59
||Zika virus strain FLR
||Zika virus strain P6-740
||Zika virus strain R103451
||Zika virus strain H/PAN/2015/CDC-259359
||Zika virus strain H/PAN/2015/CDC-259364
||Zika virus strain R116265
||Quantitative Genomic RNA from Zika virus strain MR 766
||Quantitative Genomic RNA from Zika virus strain PRVABC59
||Quantitative Synthetic Zika virus RNA
||Monoclonal antibody to Flavivirus group antigen – New!
||Monoclonal Anti-Zika virus envelope (E) protein, Clone ZV-2 (produced in vitro)
||Monoclonal Anti-Zika virus envelope protein, Clone ZV-16 (Immunoglobin G Mouse) - New!
||Aedes albopictus clone C6/36 cells
||Eagle’s Minimum Essential Medium (EMEM)
||Fetal Bovine Serum (FBS)
||Molecular Grade Water
Zika virus is a vector-borne pathogen that is spread among humans primarily through the bite of infected Aedes mosquitoes. With outbreaks occurring throughout regions in Central and South America, preventing the spread of this disease has become a top priority. ATCC strains and nucleic acid preparations serve as critical controls in research and validation, and are authenticated and backed by polyphasic testing—ensuring the consistency and reliability you have come to trust from ATCC.
The WHO estimates that vector-borne diseases contribute to 17% of the estimated global burden of infectious diseases. The development of rapid diagnostic tools and innovative vaccines is essential for improving patient outcomes and preventing the further emergence and spread of disease. Get started on your vector-borne research with microorganisms and nucleic acids from ATCC!
Tools for Clinical Research
Clinical research is vital in the development of new and better ways to accurately detect genetic, hereditary, and infectious diseases. From human cancer cell lines and microorganisms to synthetic and genomic nucleic acids, ATCC has the reference materials you need for the development and verification of rapid and reliable diagnostic tools!